ORAMED PHARMACEUTICALS INC. | Business Contracts

Oravax Stock Option Agreement (Filed With SEC on March 6, 2023)

Oravax Medical, Inc. 2021 Long-Term Incentive Plan (Filed With SEC on March 6, 2023)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on March 6, 2023)

Description of Securities (Filed With SEC on March 6, 2023)

License Agreement, dated as of March 18, 2021, by and between Oramed Pharmaceuticals Inc., Oramed Ltd. and Oravax Medical Inc (Filed With SEC on March 19, 2021)

Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement (Filed With SEC on March 6, 2023)

Second Amendment, dated October 25, 2022, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on March 6, 2023)

Employment Agreement by and between Oramed Ltd. and Nadav Kidron, entered into as of November 1, 2022 (Filed With SEC on March 6, 2023)

Consulting Agreement by and between Oramed Pharmaceuticals Inc. and Shnida Ltd., entered into as of November 1, 2022, for the services of Nadav Kidron (Filed With SEC on March 6, 2023)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on May 12, 2022)

Employment Agreement, dated July 25, 2021, by and between the Company and Michael Rabinowitz (Filed With SEC on November 24, 2021)

Amendment, dated September 19, 2021, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron (Filed With SEC on November 24, 2021)

Amendment, dated September 19, 2021, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (Filed With SEC on November 24, 2021)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 24, 2021)

First Amendment, dated September 19, 2021, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on November 24, 2021)

First Amendment, dated September 19, 2021, to Employment Agreement, by and between Oramed Ltd. and Joshua Hexter (Filed With SEC on November 24, 2021)

Form of Securities Purchase Agreement, dated as of November 3, 2021 between the Company and each Purchaser in the Offering (Filed With SEC on November 4, 2021)

Engagement Letter, dated as of November 2, 2021, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on November 4, 2021)

Equity Distribution Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on September 1, 2021)

Equity Distribution Agreement, dated July 15, 2021, by and between the Company and Canaccord Genuity (Filed With SEC on July 15, 2021)

Representative Form of Indemnification Agreement between Oramed Pharmaceuticals Inc. and each of its directors and officers (Filed With SEC on July 14, 2021)

Employment Agreement, dated May 23, 2021, between Oramed Ltd. and David Silberman (Filed With SEC on July 14, 2021)

Equity Distribution Agreement, dated June 16, 2021, by and between the Company and Canaccord Genuity (Filed With SEC on June 16, 2021)

Second Amendment, dated February 8, 2021, to Employment Agreement, entered into as of May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (Filed With SEC on April 13, 2021)

Stockholders Agreement, dated as of March 18, 2021, by and between Oramed Pharmaceuticals Inc., Akers Biosciences Inc., Premas Biotech PVT Ltd., Cutter Mill Capital LLC, and Run... (Filed With SEC on March 19, 2021)

Equity Distribution Agreement, dated December 1, 2020, by and between the Company and Canaccord Genuity (Filed With SEC on December 1, 2020)

Description of Securities (Filed With SEC on November 24, 2020)

Clinical Research Organization Services Agreement dated September 16, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (Filed With SEC on September 18, 2020)

Clinical Research Organization Services Agreement dated September 2, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (Filed With SEC on September 9, 2020)

Amendment to the Service Agreement, dated January 10, 2020, between KNRY Ltd. and Oramed Ltd (Filed With SEC on April 6, 2020)

Amendment to the Equity Distribution Agreement, dated February 10, 2020, between Canaccord Genuity LLC and Oramed Pharmaceuticals Inc (Filed With SEC on April 6, 2020)

Form of Underwriters Warrant (Filed With SEC on February 28, 2020)

Underwriting Agreement, dated February 27, 2020, between Oramed Pharmaceuticals Inc. and National Securities Corporation (Filed With SEC on February 28, 2020)

Representative Form of Indemnification Agreement between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on January 9, 2020)

First Amendment, dated December 19, 2019, to Employment Agreement, entered into as of May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (Filed With SEC on January 9, 2020)

Employment Agreement, dated August 18, 2019, between Oramed Ltd. and Joshua Hexter (Filed With SEC on November 27, 2019)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 27, 2019)

Form of Notice of Stock Option Award and Stock Option Award Agreement (Filed With SEC on November 27, 2019)

Description of Securities (Filed With SEC on November 27, 2019)

Equity Distribution Agreement, dated September 5, 2019, by and between the Company and Canaccord Genuity (Filed With SEC on September 5, 2019)

Employment Agreement, dated May 16, 2019, between Oramed Ltd. and Avraham Gabay (Filed With SEC on July 10, 2019)

Amendment #2 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (Filed With SEC on July 10, 2019)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on July 10, 2019)

Amendment #1 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (Filed With SEC on July 10, 2019)

Consulting Agreement, dated December 12, 2018, between Oramed Ltd. and Joshua Hexter (Filed With SEC on January 14, 2019)

ORAMED PHARMACEUTICALS INC. (45)